Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma 1Melanoma 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 38fludarabine 30Rituximab 26obinutuzumab 10Bendamustine Hydrochloride 10fludarabine phosphate 9pembrolizumab 8Specimen Handling 7Etoposide 7venetoclax 6Vincristine 6Prednisone 6Magnetic Resonance Spectroscopy 6Leukapheresis 6Lenalidomide 6ibrutinib 5Inotuzumab Ozogamicin 5Immunotherapy, Adoptive 5Doxorubicin 5Biopsy 5ublituximab 4tazemetostat 4glofitamab 4Interleukin-2 4Dexamethasone 4Cytarabine 4pomalidomide 3polatuzumab vedotin 3Radiation 3Nivolumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, B-Cell × Nanoparticles × Clear all
NCT03003546 2023-06-15

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Mayo Clinic

Phase 1 Completed
9 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡